Zymeworks stock fell 2.14 percent as 2026 guidance reset

Published on 10/07/2026 at 00:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zymeworks stock was last at USD 25.65 on October 6, 2026, with a USD 1.9 billion market cap. The company guides to USD 278 million to USD 292 million in 2026 revenue.

ZYME, US98985Y1082, Illustration mit AI erstellt.

Zymeworks stock (ISIN US98985Y1082) was last at USD 25.65 on Nasdaq on October 6, 2026, down 2.14 percent from the prior session. The decline leaves the biotechnology company 18.2 percent below its 52-week high of USD 31.34, while its market capitalization stood at USD 1.9 billion.

Guidance follows Theravance deal

The central business change is the completed acquisition of Theravance Biopharma and its YUPELRI profit-sharing rights. According to Zymeworks in its September 28, 2026 release, the company expects 2026 total revenue of USD 278 million to USD 292 million and adjusted EBITDA of USD 114 million to USD 128 million.

The guidance marks a new operating framework after the transaction, with YUPELRI collaboration revenue included in the total. Zymeworks said first-half 2026 YUPELRI sales reached USD 133.1 million and generated USD 38.4 million in collaboration revenue for Theravance Biopharma.

Cash flow comes with debt service

The acquisition adds a recurring commercial asset, but the financing structure limits the near-term cash retained by Zymeworks. The company used a USD 350 million non-recourse note and USD 217.5 million of existing cash, while 75 percent of YUPELRI profit-share cash flows will service the note until repayment.

Zymeworks also cited 25 percent growth in YUPELRI hospital sales in the second quarter of 2026. A potential USD 100 million TRELEGY ELLIPTA milestone payment is expected in the first quarter of 2027 if the required sales condition is met, giving the balance sheet another possible funding event.

Analysts see a wider valuation gap

The Wall Street Journal lists a Buy consensus based on 13 analysts, with a 12-month price-target range of USD 32.00 to USD 60.00 and an average of USD 41.23, according to its September 28, 2026 market page. The average target lies 60.7 percent above the October 6 price of USD 25.65, a wider gap than the stock's 18.2 percent distance below its 52-week high.

For investors, the next test is whether the acquired cash-flow stream can support the revenue guidance while the note absorbs most of the YUPELRI profit share. Zymeworks is scheduled to report third-quarter 2026 results on November 10, 2026, according to Makkler.

ZYME stock stays below its yearly high

Zymeworks stock was last at USD 25.65 on Nasdaq at 4:00 p.m. ET on October 6, 2026, with a session range of USD 25.51 to USD 26.79 and volume of 1,037,176 shares.